Currently, the EAU guideline had no recommendation of the conventional anti-androgen regimens use in the sequential treatment of metastatic prostate cancer except combination with LH-RH agonists in the beginning to compress the testosterone surge (Cornford et al., 2017). This evidence concerns the gene GNRH1 and metastatic prostate carcinoma.